Oncopeptides AB (publ) (ONPPF)
USD 0.27
(0.0%)
USD 0.27
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 238.37 Million SEK | -38.14% |
| 2022 | 385.32 Million SEK | -12.3% |
| 2021 | 439.37 Million SEK | -53.59% |
| 2020 | 946.75 Million SEK | -4.7% |
| 2019 | 993.48 Million SEK | 123.49% |
| 2018 | 444.53 Million SEK | -7.36% |
| 2017 | 479.82 Million SEK | 762.48% |
| 2016 | 55.63 Million SEK | 1163.8% |
| 2015 | 4.4 Million SEK | -66.46% |
| 2014 | 13.12 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 199.69 Million SEK | -16.23% |
| 2024 Q2 | 452.92 Million SEK | 126.81% |
| 2023 Q1 | 316.88 Million SEK | -17.76% |
| 2023 Q2 | 355.99 Million SEK | 12.34% |
| 2023 FY | 238.37 Million SEK | -38.14% |
| 2023 Q3 | 294.97 Million SEK | -17.14% |
| 2023 Q4 | 238.37 Million SEK | -19.19% |
| 2022 Q2 | 149.13 Million SEK | -42.87% |
| 2022 Q3 | 475.99 Million SEK | 219.17% |
| 2022 Q4 | 385.32 Million SEK | -19.05% |
| 2022 FY | 385.32 Million SEK | -12.3% |
| 2022 Q1 | 261.06 Million SEK | -40.58% |
| 2021 Q1 | 701.86 Million SEK | -25.87% |
| 2021 Q2 | 1.63 Billion SEK | 133.64% |
| 2021 Q3 | 827.45 Million SEK | -49.54% |
| 2021 Q4 | 439.37 Million SEK | -46.9% |
| 2021 FY | 439.37 Million SEK | -53.59% |
| 2020 Q2 | 1.04 Billion SEK | 56.44% |
| 2020 Q1 | 666.1 Million SEK | -32.95% |
| 2020 FY | 946.75 Million SEK | -4.7% |
| 2020 Q4 | 946.75 Million SEK | -28.37% |
| 2020 Q3 | 1.32 Billion SEK | 26.84% |
| 2019 Q2 | 703.98 Million SEK | -16.33% |
| 2019 FY | 993.48 Million SEK | 123.49% |
| 2019 Q1 | 841.33 Million SEK | 89.26% |
| 2019 Q3 | 1.14 Billion SEK | 62.52% |
| 2019 Q4 | 993.48 Million SEK | -13.17% |
| 2018 Q2 | 642.41 Million SEK | -13.07% |
| 2018 Q4 | 444.53 Million SEK | -19.56% |
| 2018 FY | 444.53 Million SEK | -7.36% |
| 2018 Q1 | 739.04 Million SEK | 54.02% |
| 2018 Q3 | 552.61 Million SEK | -13.98% |
| 2017 Q3 | 527.59 Million SEK | -11.47% |
| 2017 Q2 | 595.96 Million SEK | -8.49% |
| 2017 Q4 | 479.82 Million SEK | -9.05% |
| 2017 Q1 | 651.22 Million SEK | 1070.59% |
| 2017 FY | 479.82 Million SEK | 762.48% |
| 2016 Q4 | 55.63 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 55.63 Million SEK | 1163.8% |
| 2015 FY | 4.4 Million SEK | -66.46% |
| 2014 FY | 13.12 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 52.7 Million USD | -352.322% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1896.397% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -83.071% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -43075.034% |
| Qrons Inc. | 420.00 USD | -56756566.667% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -1537.179% |
| CSL Limited | 38.02 Billion USD | 99.373% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -2158.651% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -12073.391% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -67311.352% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -753.056% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -49504.521% |
| Rebus Holdings, Inc. | 5000.00 USD | -4767460.0% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -10319293.939% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -30832.311% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -34573.87% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -513.633% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -3201.743% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -312101.063% |
| SQZ Biotechnologies Company | 107.18 Million USD | -122.395% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -16546.136% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -329310.627% |
| Mesoblast Limited | 667.9 Million USD | 64.309% |
| Marizyme, Inc. | 22.01 Million USD | -982.794% |
| Genus plc | 1.02 Billion USD | 76.832% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -17449.047% |
| Pharming Group N.V. | 462.85 Million USD | 48.498% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -7095.205% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -47667.409% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -37918.82% |
| ContraFect Corporation | 20.67 Million USD | -1052.754% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -60965.257% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -62273.717% |
| IMV Inc. | 31.33 Million USD | -660.77% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -5649.559% |
| MultiCell Technologies, Inc. | 126.22 USD | -188859034.844% |
| ONE Bio Corp. | 70.08 Million USD | -240.125% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -25267.755% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -85.494% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -55116.648% |
| Q BioMed Inc. | 3.51 Million USD | -6680.738% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -577.614% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -91135.738% |
| Biomind Labs Inc. | 73.81 Thousand USD | -322822.283% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 46.589% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -16352.99% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -694.198% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -8579.859% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -9057.128% |
| GB Sciences, Inc. | 103.44 Thousand USD | -230346.047% |
| Alpha Cognition Inc. | 2.45 Million USD | -9621.104% |
| HST Global, Inc. | 1526.00 USD | -15621000.917% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -24028.134% |
| Halberd Corporation | 10.13 Thousand USD | -2352856.273% |
| Enzolytics Inc. | 361.7 Million USD | 34.096% |
| Agentix Corp. | 261.39 Thousand USD | -91095.599% |
| Resverlogix Corp. | 8.11 Million USD | -2837.498% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -12593.995% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 94.752% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -399.723% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -37166.593% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1046289.535% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -2563.693% |
| AVAX Technologies, Inc. | 7.37 Million USD | -3131.299% |
| Zenith Capital Corp. | 7410.00 USD | -3216877.058% |
| Genscript Biotech Corporation | 3.38 Billion USD | 92.961% |
| Ember Therapeutics, Inc. | 184.00 USD | -129553160.87% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -73975.064% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -91105.369% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -25588.364% |
| Kadimastem Ltd | 2.3 Million USD | -10245.908% |
| Helix BioMedix, Inc. | 3.02 Million USD | -7780.04% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -417418.478% |
| LadRx Corporation | 2.3 Million USD | -10228.864% |
| Cell Source, Inc. | 195.17 Thousand USD | -122038.023% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -67311.352% |
| NovAccess Global Inc. | 62.24 Thousand USD | -382848.85% |
| Affymax, Inc. | 7.44 Million USD | -3102.714% |
| Itoco Inc. | 1.4 Million USD | -16926.124% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -249100.79% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -224784.906% |
| Mobile Lads Corp. | 52.00 USD | -458419130.769% |
| CytoDyn Inc. | 11.13 Million USD | -2040.607% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -166630.549% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1333110.291% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -61740.709% |
| SYBLEU INC | 330.46 Thousand USD | -72033.459% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -58123.056% |
| International Stem Cell Corporation | 5.39 Million USD | -4322.597% |
| Bioxytran, Inc. | 137.63 Thousand USD | -173091.996% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -1488.993% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1337.831% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -301644.304% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -27468.445% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -3071.185% |
| Neutra Corp. | 2851.00 USD | -8361106.594% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -635.598% |
| PureTech Health plc | 693.97 Million USD | 65.65% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2853.48% |
| IXICO plc | 15.84 Million USD | -1404.541% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -2778.266% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -130.709% |
| CSL Limited | 38.02 Billion USD | 99.373% |
| Cellectis S.A. | 333.99 Million USD | 28.628% |